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Nefopam, a centrally acting analgesic, has been used in the surgical setting in many countries
since the mid-1970s. However, clinical trials provide contflicting results for its analgesic
potency. We performed a systematic search (multiple databases, bibliographies, any language,
to January 2008) for randomized, placebo-controlled trials of nefopam for the prevention of
postoperative pain. Data were combined using classic methods of meta-analyses and were
expressed as weighted mean difference (WMD), relative risk (RR), and number needed to
treat/harm (NNT/H) with 95% confidence interval (CI). Nine trials (847 adult patients, 359
received nefopam) were included. Nefopam (cumulative doses, 20–160 mg) was given orally or
i.v., as single or multiple doses, or as a continuous infusion. Compared with placebo, cumulative
24 h morphine consumption was decreased with nefopam: WMD 213 mg (95% CI 217.9
to 28.15). Pain intensity at 24 h was also decreased: on a 100 mm visual analogue scale,
WMD 211.5 mm (95% CI 215.1 to 27.85). The incidence of tachycardia was increased with
nefopam (RR 3.12, 95% CI 1.11–8.79; NNH 7), as was the incidence of sweating (RR 4.92,
95% CI 2.0–12.1; NNH 13). There is limited evidence from the published literature that
nefopam may be a useful non-opioid analgesic in surgical patients. The analgesic potency seems
to be similar to non-steroidal anti-inflammatory drugs. However, dose responsiveness and
adverse effect profile remain unclear, and the role of nefopam as part of multimodal analgesia
needs to be established. Data in children are lacking.
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In the early 1970s, nefopam was developed as an anti-
depressant and was also used as a myorelaxant for the
treatment of spasticity.15 The additional analgesic property
was soon recognized,10 and although the mechanism of
analgesia is not completely understood, it appears that
nefopam is a centrally acting, non-opioid analgesic that
inhibits reuptake of serotonin, norepinephrine, and
dopamine.23
Nefopam is a benzoxazocine and is a cyclized analogue
of diphenhydramine (an antihistamine), and its chemical
structure is close to orphenadrin (an antimuscarinic).
Nefopam is synthesized in four steps from O-benzoyl
benzoic acid and is pharmacologically unrelated to any
other known analgesic.13 Plasma half-life is 3–5 h; plasma
peak concentrations are reached 15–20 min after i.v. injec-
tion, and after 30 min during a continuous infusion. Owing
to a first-pass metabolism, oral bioavailability is only 40%.
Nefopam undergoes extensive hepatic biotransformation to
desmethylnefopam (which seems to be biologically active)
and N-oxide-nefopam.2 Protein binding is 75%, and the
major route of elimination (87%) is renal whereas a small
part (8%) is excreted in the faeces. Ninety-five per cent of
an initial dose is excreted within 5 days, 5% as unchanged
substance.13
Nefopam has been used extensively in many countries
for the treatment of acute and chronic malignant and non-
malignant pain, often despite the lack of valid clinical trial
data. Some studies have suggested that in the surgical
setting, nefopam 20 mg was equipotent to morphine 6–12
mg,26 or to meperidine 50 mg.28 Some authors also
reported on a morphine-sparing effect of 30–50%.18 20
However, others were unable to confirm these results,19
and the role of nefopam as an adjuvant to opioid-analgesia
in patients undergoing surgery has remained obscure.
Nefopam is generally considered to be safe and well tole-
rated. Reported adverse effects are mostly minor and include
drowsiness, nausea and vomiting, and sweating.6 14 20
Potentially more serious adverse effects are confusion and
tachycardia.20 30 Unlike non-steroidal anti-inflammatory
drugs, nefopam has no effect on platelet function,5 and, in
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contrast to opioids, this drug does not seem to increase the
risk of respiratory depression.11 In this quantitative systema-
tic review, we aimed to quantify the analgesic efficacy and
the adverse effect profile of nefopam when used as an
analgesic for the prevention of postoperative pain.
Methods
Literature search
MEDLINE, the Cochrane Library, EMBASE, WHOLIS,
the African Index Medicus, and LILACS were searched
using the term ‘nefopam’ either alone or in association
with ‘pain’. Trials studying the anti-shivering effect of
nefopam16 were excluded using the command ‘NOT shi-
vering’ in the title, abstract, and keywords. Additional
trials were identified from the reference lists of retrieved
reports. The last search was performed in January 2008.
Searches were without language restriction and authors
were contacted for supplemental data or specific questions
about their trials.
We included trials that compared nefopam with an
inactive control group (placebo or no treatment) for the
prevention of postoperative pain and that reported on pain
outcomes or adverse effects. We limited our search to
randomized trials in humans. Data from abstracts, letters,
experimental studies in healthy volunteers, narrative
reviews, animal studies, and studies with ,10 patients per
group were not considered.
One author (M.S.E.) extracted information on patients,
surgery, anaesthesia, nefopam and postoperative analgesic
regimens, pain outcomes, and adverse effects. Two other
authors independently checked all extracted data.
Appropriate pain outcomes were pain intensity at rest and
on movement (or during coughing), and cumulative post-
operative morphine consumption.
Continuous outcomes were extracted as means and stan-
dard deviations or standard errors. When these data were
not reported, we contacted the authors. If they did not
respond, and the data were presented graphically, we
attempted to extract the data from the graphs. Data from
continuous 0–10 cm visual analogue scales for pain inten-
sity were converted to a 0–100 mm scale. Binary out-
comes (for instance, adverse effects) were extracted as the
presence or absence of the effect. Definitions of adverse
effects were taken as reported in the original trials.
We applied a modified four-item, seven-point Oxford
scale to assess the adequacy of data reporting (randomiz-
ation, concealment of treatment allocation, blinding,
description of withdrawals) of all included trials.8 As we
included only randomized trials, the minimum score was 1.
One author scored all included studies (M.S.E.). Scores
were independently checked by the two other authors and
discrepancies were resolved by discussion.
Meta-analysis
For continuous outcomes, we computed weighted mean
differences (WMD) with 95% confidence interval (CI).
For dichotomous outcomes, we calculated relative risks
(RR) with 95% CI. If the 95% CI around the WMD or RR
did not include 1, we assumed that the difference between
nefopam and control was statistically significant at the 5%
level. To estimate the clinical relevance of a beneficial or
harmful effect, we calculated numbers needed to treat
(NNT) or to harm (NNH); a 95% CI around the NNT/H
point estimate was computed when the difference was stat-
istically significant.29 We were using a fixed effect model
throughout. Heterogeneity was formally tested using both
the conventional x2 statistics and the I2 statistics (i.e. the
proportion of total variation in the estimates of a treatment
effect that is due to heterogeneity between the studies).
Analyses were conducted using Review Manager (version
4.2, Cochrane Collaboration) and Microsoft Excelw 2003
for Windows XPw.
Results
Retrieved trials
We identified 70 trials but subsequently excluded 61
(Fig. 1). Two reports were unavailable,4 27 and one was
excluded as data reporting was inappropriate.31 One report
was published twice.1 25 We included the more recently
published study1 as the data reported were more complete.
We contacted three authors for supplementary infor-
mation.19 20 30 One answered and the data were included
in our analyses.20 One was unable to provide the necessary
data, but some information could be extracted from the
published figures.30 Finally, one did not answer, and as no
relevant efficacy data could be extracted from the pub-
lished report, only data on drug-related harm could be
used for analysis.19
We eventually analysed data from nine valid random-
ized trials, published between 1974 and 2007, with data
from 847 adult patients, of which 359 received nefopam,
136 received another analgesic drug (ketamine, diclofenac,
tilidine, propoxyphene, or proparacetamol), and 352
received an inactive control treatment (placebo or no
treatment).1 3 6 12 14 18– 20 30 Five studies were performed in
France, two in the UK, one in Belgium, and one in the
USA. Group sizes ranged from 20 to 102 patients. The
median score for quality of data reporting was 4 (range
1–7). Surgery was major abdominal in four trials,
episiotomy in two, and hip arthroplasty, gynaecologic or
orthopaedic, or dental extraction in one each. All patients
underwent general anaesthesia (Table 1).
A large variety of nefopam regimens were tested. In
two trials for each regimen, nefopam was administered as
a continuous i.v. infusion, as repeat i.v. injections, or as a
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single i.m. injection; in one trial for each, it was adminis-
tered as repeat i.m. injections, as a single i.v. injection, or
as a single oral dose. Cumulative doses ranged from 20 to
160 mg for i.v., from 45 to 90 mg for oral, and from 20 to
100 mg for i.m. regimens (Table 1). Follow-up was 60
min in one trial, 6 or 7 h in two further trials, 24 h in four,
and 48 h in two trials.
Pain outcomes
The studies reported on a large variety of pain outcomes,
and few of these were reported in more than two trials.
Six trials reported on cumulative morphine consumption
at various postoperative times: three of those reported on
cumulative morphine consumption at 24 h.6 18 20 They
used nefopam 20 mg i.m. every 6 h for 24 h (cumulative
dose, 100 mg) in patients undergoing upper abdominal
surgery,18 or 20 mg i.v. every 4 h for 24 h (cumulative
dose, 120 mg) in patients undergoing hepatic resection,20
or hip arthroplasty.6 Average cumulative 24 h morphine
consumption in controls was 47 mg. When the data were
combined, cumulative 24 h morphine consumption was
significantly decreased with nefopam: WMD 213 mg
(95% CI 217.9 to 28.15) (Fig. 2). The data were too
sparse to allow testing for dose–response.
Seven studies reported on postoperative pain intensity,
but only three used a conventional 0–10 cm or 0–100 mm
visual analogue pain scale. All three reported on pain
intensity at rest at 24 h.6 20 30 Two of them tested nefopam
20 mg i.v. every 4 h for 24 h (cumulative dose, 120 mg) in
patients undergoing hepatic resection,20 or hip arthroplasty.6
The third trial tested a continuous infusion of nefopam (80
mg during 24 h) during 2 days (cumulative dose, 160 mg)
in patients undergoing abdominal laparotomy.30 In controls,
average pain intensity at 24 h ranged from 24 to 40 mm on
the 100 mm visual analogue scale. When the data were
combined, average pain intensity was significantly
decreased in patients receiving nefopam: WMD 211.5 mm
(95% CI 215.1 to 27.85) (Fig. 3). The data were too
sparse to allow testing for dose responsive.
One trial reported on pain intensity during coughing.20 In
controls, average pain intensity on coughing at 24 h was 60
mm on the 100 mm visual analogue scale; in the nefopam
group, average pain intensity on coughing at 24 h was 45
mm, an improvement that was statistically significant.
Data from active controlled trials
Five studies had a supplementary group with an active
comparator.1 3 12 14 20 In patients following hepatic resec-
tion, supplemental morphine requirements were signifi-
cantly decreased and analgesia was consistently superior
with nefopam 20 mg i.v. 4 hourly compared with propara-
cetamol 2 g i.v. 6 hourly.20 There was no difference
between diclofenac 75 mg i.m. and nefopam 20 mg i.m. in
relieving pain in outpatients who received general anaes-
thesia for surgical removal of third molars.12 Postoperative
morphine requirements were similar with nefopam 20 mg
i.v. and ketamine 10 mg i.v. in patients undergoing major
surgery.14 Finally, the analgesic efficacy of nefopam 0.66
mg kg21 i.m. was similar to tilidine 1.67 mg kg21 i.m.
after gynaecologic or orthopaedic surgery,1 and nefopam
Not placebo controlled (n=29)
Treatment, not prevention, of postoperative pain (n=12)
Analgesic effect of nefopam is not subject of study (n=7)
Experimental study design (n=5)
Duplicate publication (n=1)
Inappropriate study design (n=2)
Not available (n=2)
Narrative review (n=2)
Incomplete data reporting (n=1)
9 RCTs included (847 patients randomised: 359 nefopam, 352 placebo, 136 another analgesic*)
10 RCTs
70 potentially relevant trials
Fig 1 Flow chart of retrieved, excluded, and analysed trials. RCT, randomized controlled trial. *Ketamine, diclofenac, tilidine, and propoxyphene.
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Table 1 Included trials testing nefopam for the management of postoperative pain. Randomization: 0, none; 1, mentioned; 2, describedþadequate. Concealment: 0 no, 1 yes. Blinding: 0 none, 1 mentionend but
unclear, 2 describedþadequate. Follow-up: 0, not adequately described; 1, described but incomplete; 2, describedþadequate. PACU, post-anaesthetic care unit; PCA, patient-controlled analgesia. All trials were
performed in adults. *(), no. of analysed patients; [], data not considered
Reference Comparison* Nefopam regimen Surgery Anaesthesia Postoperative pain
management
Quality of data reporting
Time point of
administration
Cumulative
dose
Randomization Concealment Blinding Follow-up
Abeloos and
colleagues1
1. Nefopam 0.66 mg kg21
i.m. (34)
End of surgery 40 mg Gynaecologic,
orthopaedic
Halothane or enflurane,
nitrous oxide
N/A 1 1 1 2
[2. Tilidine 1.67 mg kg21
i.m. (34)]
3. Placebo (33)
Bloomfield and
colleagues3
1. Nefopam 90 mg p.o.
(25)
After intervention 1. 90 mg Episiotomy No information N/A 2 1 2 2
2. Nefopam 45 mg p.o.
(25)
2. 45 mg
[3. Propoxyphene 65 mg
p.o. (25)]
4. Placebo (25)
Du Manoir and
colleagues6
1. Nefopam 20 mg i.v. (98) At skin closure 20 mg Hip arthroplasty Thiopental or propofol,
sufentanil, isoflurane, nitrous
oxide
PCA morphine 1 0 1 2
2. Placebo (102)
Goucke and
colleagues12
[1. Diclofenac 75 mg i.m.
(23)]
After induction of
anaesthesia
20 mg Dental extraction Methohexitone, halothane,
nitrous oxide
Acetaminophen on
demand
1 0 0 0
2. Nefopam 20 mg i.m.
(22)
3. No treatment (21)
Kapfer and
colleagues14
1. Placebo (21) After surgery in
PACU
20 mg Major Thiopental, sufentanil,
isoflurane, nitrous oxide
Morphine on demand 2 1 1 2
[2. Ketamine 10 mg i.v.
(22)]
3. Nefopam 20 mg i.v. (22)
McLintock and
colleagues18
1. Nefopam 20 mg i.m.
(23)
At skin closure 100 mg Abdominal Thiopental or propofol,
sufentanil, isoflurane, nitrous
oxide
PCA morphine 1 0 1 2
2. Placebo (26)
Merle and
colleagues19
1. Nefopam 20 mg i.v.þ80
mg 24 h21 infusion (20)
End of surgery 1. 100 mg Urologic
laparotomy
Propofol, sufentanil,
desflurane, nitrous oxide
PCA morphine 2 1 2 2
2. Nefopam 20 mg
i.v.þ120 mg 24 h21
infusion (20)
2. 140 mg
3. Placebo (20)
Mimoz and
colleagues20
1. No treatment (38) End of surgery 120 mg Hepatic resection Pentobarbital, midazolam,
sufentanil, nitrous oxide
PCA morphine 1 1 0 2
2. Nefopam 20 mg 4 h21
i.v. (39)
[3. Proparacetamol IV
(38)]
Tramoni and
colleagues30
1. Nefopam 160 mg 48 h21
infusion (31)
End of surgery 160 mg Abdominal
laparotomy
Thiopental, remifentanil,
isoflurane
PCA morphine 1 0 1 2
2. Placebo (31)
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45 or 90 mg orally was more efficacious than propoxy-
phene 65 mg orally in the relief of post-episiotomy pain.3
Adverse effects
Two trials reported on the incidence of postoperative
tachycardia.14 20 Tachycardia was defined as a heart rate
.100 beats min21 for at least 5 min,14 or as 120 beats
min21 for more than 30 min.20 When the data were com-
bined, the risk of tachycardia was significantly increased
in patients receiving nefopam: RR 3.12 (95% CI 1.11–
8.79), NNH 7 (Table 2).
Seven trials reported on the incidence of postoperative
sweating.1 3 6 14 18 20 30 When the data were combined, the
risk of sweating was significantly increased with nefopam:
RR 4.92 (95% CI 2.0–12.1), NNH 13 (Table 2). Other
reported adverse effects were sedation, nausea or vomiting,
drowsiness, dry mouth, dizziness, and confusion: none of
these was significantly associated with nefopam (Table 2).
Discussion
There are three main findings from this meta-analysis.
First, nefopam, when used in adults undergoing surgery
has a morphine-sparing effect in the postoperative period.
Secondly, nefopam decreases pain intensity at 24
h. Thirdly, nefopam increases the risk of tachycardia and
of sweating.
These results suggest that nefopam has a potential in the
control of postoperative pain as demonstrated by the finding
that cumulative 24 h morphine consumption was decreased
by almost 30%. However, this outcome has to be interpreted
with caution as it was reported in only three trials with data
on 306 patients. Postoperative morphine-sparing per se is a
surrogate of the efficacy of an adjuvant analgesic that is
used in the perioperative period. However, the degree of
morphine sparing may be used to compare indirectly the
efficacy of analgesic adjuvants. For instance, nefopam’s
morphine-sparing effect appeared to be more pronounced in
comparison with acetaminophen,9 24 but similar to ketamine
or non-steroidal anti-inflammatory drugs.8 9 We were unable
to establish dose responsiveness for nefopam’s morphine-
sparing effect as the data were too sparse and the nefopam
regimens were too variable. Despite nefopam’s statistically
significant morphine-sparing effect, there was no evidence
of a decrease in the incidence of morphine-related adverse
effects. This phenomenon has been observed with other
non-opioid analgesics, and thus the clinical relevance of the
morphine sparing is controversial.7
There was a statistically significant decrease in pain
intensity at rest at 24 h. As with the morphine sparing, this
outcome has to be interpreted with caution due to the small
number of trials. However, the result suggests that a patient
who receives nefopam as an adjuvant to a morphine-based
analgesic regimen is likely to have the pain intensity at rest
decreased from 50 to 40, or from 40 to 30, on a 100 mm
scale. This degree of efficacy may be regarded as clinically
relevant, and again, it seemed to be more pronounced in
comparison with acetaminophen,9 and to be similar to
ketamine or non-steroidal anti-inflammatory drugs.8 9 Pain
intensity on movement, perhaps the most relevant endpoint
in this context, was reported in one single study only.
Indirect comparisons from placebo-controlled trials
suggest that nefopam was more analgesic than acetamino-
phen and equianalgesic with ketamine or non-steroidal anti-
inflammatory drugs. Direct comparisons between nefopam
and other analgesics may be used to validate these findings.
Indeed, nefopam appeared to be more analgesic than pro-
paracetamol,20 equianalgesic with diclofenac12 or keta-
mine,14 and similar or even more analgesic compared with
the weak opioids, tilidine or propoxyphene.1 3
Nefopam was generally well tolerated. The incidence of
sweating increased significantly with nefopam, but this
side-effect could be classified as uncomfortable rather than
a true medical problem. About one in 13 patients complain
of sweating. Tachycardia was also significantly more
frequently associated with nefopam: one in seven patients
develop tachycardia when exposed to this drug.
Tachycardia may be undesirable in patients with limited
cardiac function.
Life-threatening adverse effects have been reported in
relation to nefopam overdose. An accidental overdose was
McLintock and colleagues18 23 44.1 (34.5) 26 62.5 (35.2) 6.20 –18.4 (–37.9 to 1.14)
Mimoz and colleagues20 36 24.6 (18.1) 38 45.2 (18.7) 33.8 –20.6 (–29.0 to –12.2)
Du Manoir and colleagues6 93 34.5 (19.6) 90 42.7 (23.6) 60.0 –8.20 (14.5 to –1.90)
–40 –30 –20 –10 0 10
WMD (95% CI)
ALL 152 154 –13.0 (–17.9 to –8.15)
WMD (95% CI)n Mean (SD)
Nefopam Control
n Mean (SD) WeightReference
Fig 2 Cumulative 24 h morphine consumption. WMD, weighted mean difference; CI, confidence interval. Test for heterogeneity P¼0.06, I2¼64.8%.
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reported in a 77-yr-old man who was undergoing sple-
nectomy.22 The postoperative analgesic regimen con-
sisted of patient-controlled analgesia with morphine,
wound infiltration with ropivacaine, acetaminophen, and
a continuous infusion of nefopam 100 mg day21. One
hour after the initial 20 mg loading dose, nefopam
plasma level was 73 ng ml21, corresponding to plasma
levels previously reported after similar doses.2 17 After a
14 h continuous infusion, nefopam plasma concentration
rose unexpectedly to 135 ng ml21. At this time, the
patient developed acute neurological impairment with
disorientation, confusion, mydriasis, tachyarrhythmia
with a heart rate of 120 beats min21, and respiratory
depression necessitating tracheal intubation. Acute renal
failure and hypoproteinaemia were diagnosed. It
remained unclear whether the nefopam caused the renal
failure, or whether nefopam accumulated due to renal
failure and drug displacement related to hypoproteinae-
mia. Treatment was symptomatic and the outcome was
good.22
Our systematic review has limitations. First, several
retrieved reports could not be used for meta-analysis as
they compared nefopam with another analgesic and did
not incorporate a placebo group. As there is no gold
standard analgesic against which nefopam could be
tested, combination of data from active controlled trials
would be inappropriate. However, direct comparisons
from the retrieved reports could be used to validate the
findings of our analysis. Secondly, most trials were of
limited size; only two contained more than 40 patients
per group.3 6 Small studies of pain are more likely to
report on beneficial outcomes by random chance.21 In
addition, small studies are unlikely to report on rare but
clinically relevant adverse effects. The large variety of
reported outcomes made it difficult to combine data
from more than two trials. Many of these outcomes
were non-validated and were invented by the authors.
For instance, pain intensity was not only reported on the
widely accepted and standardized linear 10 cm or 100
mm visual analogue scale but also on a variety of
custom numerical and verbal scales, preventing com-
parison across trials. The clinical relevance of many
reported outcomes remained unclear, for example, in
one trial, patients were followed up for 60 min and pain
intensity was recorded every few minutes.14 Only one
study reported pain intensity both at rest and during
coughing.20 Adequate relief of dynamic pain allows for
early mobilization and respiratory physiotherapy and is
therefore crucial in the postoperative period. There was
no agreement on the optimal dosage regimen for
nefopam. It was given i.m., i.v., or orally, as a single or
multi-dose regimen, or as a continuous infusion.
Combining such diverse raw material data may be ques-
tionable, and testing for dose–response was impossible.
Finally, relevant data from patient groups, such as preg-
nant women, the elderly, or children, were unavailable.
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In conclusion, there is some evidence that nefopam may
be a useful non-opioid adjuvant to opioid-based, multimo-
dal analgesia in patients undergoing surgery. Further
research into this drug is necessary to establish the dose–
response of the analgesic efficacy and to define the most
useful regimen and the adverse effect profile. Trials should
be of reasonable size and should report on validated out-
comes for the measurement of pain intensity and pain
relief. Pain intensity should be recorded at rest and during
coughing or on movement. Studies of other patient popu-
lations, especially children, are warranted.
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